Evidence map›Paper›PMID 41311816›Full record

ArticleOncology letters2026

TAS-102 plus bevacizumab as salvage treatment in colorectal cancer: A retrospective study.

Keita Matsumoto, Ryoma Yokoi, Chika Mizutani, Ryuichi Asai, Jesse Yu Tajima, Masahide Endo, Yuji Hatanaka, Takeshi Horaguchi, Masahiro Fukada, Itaru Yasufuku and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Keita MatsumotoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Ryoma YokoiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Chika MizutaniDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Ryuichi AsaiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Jesse Yu TajimaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Masahide EndoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Yuji HatanakaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Takeshi HoraguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Masahiro FukadaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Itaru YasufukuDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Yuta SatoDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Yoshihiro TanakaDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Katsutoshi MuraseDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.
Nobuhisa MatsuhashiDepartment of Gastroenterological Surgery, Graduate School of Medicine, Gifu University Hospital, Gifu University, Gifu, Gifu 501-1194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The current study aimed to evaluate the efficacy and safety of TAS-102 plus bevacizumab therapy as a salvage treatment for colorectal cancer, focusing on the differences between colon and rectal cancers. The present single-center retrospective study enrolled 101 patients treated with TAS-102 between October 2016 and December 2023 (median age, 67 years; 65 men and 36 women). The tumors included 16, 23 and 62 lesions in the right colon, left colon and rectum, respectively. The chemotherapy history included fluoropyrimidine (101 patients, 100%), oxaliplatin (95 patients, 94.1%), irinotecan (82 patients, 81.2%), anti-vascular endothelial growth factor antibody (92 patients, 91.1%) and anti-epidermal growth factor receptor antibody (41 patients, accounting for 87.2% of the RAS wild-type subgroup). The median duration of TAS-102 plus bevacizumab treatment was 184 days. A subsequent line of chemotherapy was administered in 66 patients (65.3%). The progression-free survival (PFS) time was 5.6 months, whereas the overall survival (OS) time was 14.2 months. Colon and rectal cancers exhibited a PFS of 4.0 and 6.9 months, and an OS of 11.0 and 17.6 months, respectively. The results of the present study suggested that TAS-102 combined with bevacizumab in subsequent treatment may have greater efficacy in rectal cancer than in colon cancer, possibly due to the lower frequency of liver metastases in rectal cancer. However, this finding is exploratory and requires further validation via larger prospective studies.

Indexed as

colon cancerCRCrectal cancersurvivalTAS-102 plus bevacizumab

Identifiers

PMID41311816
PMCPMC12648143

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.